問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Internal Medicine

Division of Otolaryngology

Division of Hematology & Oncology

Division of Thoracic Medicine

National Taiwan University Hospital Hsin-Chu Branch (在職)

Division of Hematology & Oncology

National Taiwan University Cancer Center (在職)

Division of Hematology & Oncology

更新時間：2023-09-19

廖斌志
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

278Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

廖斌志

List

381Cases

2023-07-01 - 2030-06-30

Phase II/III

A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody) in Combination With Cemiplimab (Anti-PD-1 Antibody) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 ≥50%

  • Condition/Disease

    Advanced Non-Small Cell Lung Cancer

  • Test Drug

    REGN3767 (Fianlimab) REGN2810 (Cemiplimab)

Participate Sites
8Sites

Recruiting8Sites

2024-07-01 - 2027-08-31

Phase I/II

A Phase 1b/2, Open-label, Randomized Study of Vudalimab in Combination With Chemotherapy or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced Non-small Cell Lung Cancer

  • Condition/Disease

    Nonsquamous Non-small Cell Lung Cancer

  • Test Drug

    Vudalimab

Participate Sites
5Sites

Not yet recruiting2Sites

Recruiting3Sites

2022-05-10 - 2026-08-04

Phase III

HERTHENA–Lung02: A Phase 3, Randomized, Open-label Study of Patritumab Deruxtecan Versus Platinum based Chemotherapy in Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer (NSCLC) After Failure of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy

  • Condition/Disease

    Non-small cell lung cancer

  • Test Drug

    Patritumab Deruxtecan (U3-1402)

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites

2024-03-01 - 2028-06-30

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2024-02-06 - 2029-08-30

Phase II

Active
A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RESECTABLE EARLY STAGE (STAGE II TO IIIB [N2]) NSCLC

  • Condition/Disease

    NSCLC

  • Test Drug

    REGN3767 (Fianlimab) REGN2810 (Cemiplimab)

Participate Sites
9Sites

Not yet recruiting8Sites

Recruiting1Sites

2024-01-01 - 2030-12-31

Phase III

SUNRAY-01, A Global Pivotal Study in Participants with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum regardless of PD-L1 Expression

  • Condition/Disease

    Carcinoma, Non-Small-Cell Lung

  • Test Drug

    Carboplatin|Cisplatin|LY3537982|Pembrolizumab|Pemetrexed|Placebo

Participate Sites
14Sites

Recruiting14Sites

2020-07-01 - 2022-01-17

Phase I

A Phase 1/1b First-in-human Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR439459 Administered Intravenously as Monotherapy and in Combination With Cemiplimab in Adult Patients With Advanced Solid Tumors

  • Condition/Disease

    Malignant Solid Tumor

  • Test Drug

    SAR439459

Participate Sites
3Sites

Recruiting1Sites

Terminated2Sites

2018-06-01 - 2022-11-15

Phase I

A Phase 1/2 Open-label, Multi-center, Safety, Preliminary Efficacy and Pharmacokinetic (PK) Study of Isatuximab (SAR650984) in Combination With Atezolizumab or Isatuximab Alone in Patients With Advanced Malignancies

  • Condition/Disease

    Advanced Malignancies

  • Test Drug

    Isatuximab

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting5Sites

趙毅
Taipei Veterans General Hospital

Division of Hematology & Oncology

余明隆
Kaohsiung Municipal Gangshan Hospital

未分科

2015-07-01 - 2020-12-31

Phase II

Multicenter, open-label, single arm, Phase II study in advanced non-small cell lung cancer；Subtitle:A multicenter, open-label, single arm Phase II study to evaluate safety and efficacy of ONO-4538 in stage IIIB/IV or recurrent non-small cell lung cancer patients who are unsuited to radical radiotherapy and resistant to a platinum-base chemotherapeutic regimen.

  • Condition/Disease

    stage IIIB/IV or recurrent non-small cell lung cancer

  • Test Drug

    Opdivo®

Participate Sites
10Sites

Not yet recruiting1Sites

Terminated8Sites

陳育民
Taipei Veterans General Hospital

Division of Thoracic Medicine

楊政達
Linkou Chang Gung Medical Foundation

Division of Thoracic Medicine

2020-04-01 - 2024-03-15

Phase I/II

A Phase I, Open-Label, Multi-Center, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer

  • Condition/Disease

    Advanced Solid Tumorsand/ Small Cell Lung Cancer

  • Test Drug

    IMP4297 and Temozolomide

Participate Sites
4Sites

Recruiting4Sites

1 26 27 28 29 30 39
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB